HIMS vs. NTRA, FMS, OPCH, GH, RDNT, SHC, BTSG, VCYT, LFST, and CON
Should you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Natera (NTRA), Fresenius Medical Care (FMS), Option Care Health (OPCH), Guardant Health (GH), RadNet (RDNT), Sotera Health (SHC), BrightSpring Health Services (BTSG), Veracyte (VCYT), LifeStance Health Group (LFST), and Concentra Group Holdings Parent (CON). These companies are all part of the "healthcare" industry.
Hims & Hers Health vs.
Hims & Hers Health (NYSE:HIMS) and Natera (NASDAQ:NTRA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, community ranking, risk, profitability, media sentiment and institutional ownership.
Natera received 441 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 68.96% of users gave Natera an outperform vote while only 39.05% of users gave Hims & Hers Health an outperform vote.
In the previous week, Hims & Hers Health had 9 more articles in the media than Natera. MarketBeat recorded 24 mentions for Hims & Hers Health and 15 mentions for Natera. Hims & Hers Health's average media sentiment score of 0.64 beat Natera's score of 0.56 indicating that Hims & Hers Health is being referred to more favorably in the media.
Hims & Hers Health has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.
63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 17.7% of Hims & Hers Health shares are owned by insiders. Comparatively, 7.6% of Natera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Hims & Hers Health has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.
Hims & Hers Health presently has a consensus price target of $25.13, suggesting a potential downside of 9.60%. Natera has a consensus price target of $160.63, suggesting a potential upside of 1.43%. Given Natera's stronger consensus rating and higher probable upside, analysts clearly believe Natera is more favorable than Hims & Hers Health.
Hims & Hers Health has a net margin of 8.19% compared to Natera's net margin of -14.01%. Hims & Hers Health's return on equity of 10.97% beat Natera's return on equity.
Summary
Hims & Hers Health and Natera tied by winning 9 of the 18 factors compared between the two stocks.
Get Hims & Hers Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hims & Hers Health Competitors List
Related Companies and Tools
This page (NYSE:HIMS) was last updated on 1/20/2025 by MarketBeat.com Staff
Free HIMS Stock Alerts